Lundbeck partners with Cradle to discover and optimize brain disorder treatments. Cision Publicerad: Idag 14:00 Collaboration's initial focus will focus on two antibody programs targeting CNS diseases VALBY, Denmark & AMSTERDAM, 03 June 2026 - H. Lundbeck A/S (Lundbeck), a global biopharmaceutical company focused exclusively on brain health, and Cradle, a leading AI platform for protein engineering, today announced a partnership to help Lundbeck discover and optimize biotherapeutics that ultimately can improve patient outcomes. It is estimated that more than half of the world's population is impacted by brain disorders, and the effects are felt throughout society. Speeding up innovation time to develop high-quality biologics is a critical part of bringing effective new treatments to patients. As part of its aim to ease this burden and bring new treatments to patients in need, Lundbeck is deploying Cradle's AI-powered protein design platform to develop multiple higher-performing candidates that can accelerate breakthroughs for neurological conditions. "Lundbeck is committed to becoming a bionic company, embedding AI into how we work to complement human expertise and bring faster results," said Tarek Samad, SVP, Global Head of Research and Corporate Patents at Lundbeck. "Our partnership with Cradle fits perfectly with this commitment as their platform provides our scientists with powerful AI that fits seamlessly into our processes, strengthening our ability to discover and optimize therapeutics." The partnership is powering Lundbeck's first end-to-end AI-guided protein engineering workflow, where experimental results are continuously fed back into the model, enabling each iteration to improve prediction accuracy and accelerate convergence toward viable candidates. The platform will initially be used to advance two antibody programs targeting CNS diseases. Lundbeck's protein engineers and computational biologists will use Cradle's generative AI platform to engineer higher-quality antibody candidates while reducing the number of wet-lab iterations required to reach lead candidates. "Lundbeck has a strong biotherapeutic pipeline in CNS and is now strengthening that position with the power of AI across their research and development organization," said Stef van Grieken, CEO and Co-Founder of Cradle. "The Cradle platform has been shown in internal and partner programs to accelerate design cycles significantly. By closing the loop between computation and the lab, we can help Lundbeck reach high-quality antibody candidates faster and with fewer iterations." The Cradle partnership builds on Lundbeck's systematic embrace of AI to accelerate its Focused Innovator strategy. It complements a recently announced partnership with the Danish Centre for AI Innovation, which provides Lundbeck access to Denmark's Gefion AI supercomputer with advanced AI computing power for large-scale scientific modelling and discovery. Together, the two partnerships will strengthen Lundbeck's end-to-end AI discovery capabilities, from expanding the scientific search space to improving and accelerating specific biologic candidates. Across the organization, Lundbeck estimates AI-driven initiatives are already contributing more than 12,000 hours saved per week through efficiency gains. In drug discovery specifically, AI-enabled structural insights and predictions that once took months can now be generated in under 24 hours, while expanding the searchable scientific space by approximately 50,000x. About H. Lundbeck A/S. Lundbeck is a biopharmaceutical company focusing exclusively on brain health. With more than 70 years of experience in neuroscience, Borskollen is committed to improving the lives of people with neurological and psychiatric diseases. Brain disorders affect a large part of the world's population, and the effects are felt throughout society. With the rapidly improving understanding of the biology of the brain, Borskollen hold ourselves accountable for advancing brain health by curiously exploring new opportunities for treatments. As a focused innovator, Borskollen strive for its research and development programs to tackle some of the most complex neurological challenges. Borskollen develop transformative medicines targeting people for whom there are few or no treatments available, expanding into neuro-specialty and neuro-rare from its strong legacy within psychiatry and neurology. Borskollen is committed to fighting stigma and Borskollen act to improve health equity. Borskollen strive to create long term value for its shareholders by making a positive contribution to patients, their families and society as a whole. Lundbeck has more than 5,000 employees in more than 20 countries and its products are available in more than 80 countries. For additional information, Borskollen encourage you to visit its corporate site www.lundbeck.com and connect with Borskollen via LinkedIn. Contacts. | Anders Crillesen | Jens Høyer | | Senior Director, Corp. Communication | Vice President, Head of Investor Relations | | [email protected] | [email protected] | | +45 27 79 12 86 | +45 30 83 45 01 | | / | / | About cradle. Cradle's mission is to make engineering biology easier, quicker and more cost-effective. Its enterprise-grade AI software platform currently serves eight out of the top 25 global pharma companies, and is used across over 50 R&D programs. With Cradle, scientists can engineer better proteins, faster and more successfully, speeding up the development cycle of new therapeutics and bio-based products such as, antibodies, enzymes, and bio-based materials by 2-12x. Cradle is based in Amsterdam, The Netherlands; Zurich, Switzerland and the United States with a team of machine learning and biotech research specialists with experience at many of the world's leading technology and biotech companies, including Google, Novartis, Meta, Zymergen, Uber, Deepmind and Generate Biomedicines. Cradle is backed by IVP as well as Index Ventures and Kindred Capital. For more information, visit cradle.bio.

Cradle, an enterprise-grade AI platform for protein engineering, has appointed Marcus Schindler to its advisory board. Schindler previously served as executive vice president for research and early development and chief scientific officer at Novo Nordisk, where he oversaw pipeline development across multiple therapeutic areas. The Amsterdam and Zurich-based company now powers more than 50 protein R&D programmes globally and partners with six of the top 25 biopharma organisations, including Johnson & Johnson, AbbVie and Novo Nordisk. In 2026, Cradle announced a new partnership with Bayer for antibody discovery. Cradle's SaaS platform enables scientists to engineer proteins for various modalities including enzymes, peptides, vaccines and antibodies, accelerating early research and development by two to 12 times. The company is backed by IVP, Index Ventures and Kindred Capital.

Bayer partners with Cradle to advance ai-led drug discovery. Pharma giant Bayer has signed a three-year strategic collaboration with biotech company Cradle to advance AI-enabled antibody discovery and optimisation. Bayer aims to implement Cradle's AI software platform, used for protein engineering, to scale its drug discovery and development efforts. The company intends to integrate Cradle's platform with existing R&D workflows to enhance lead generation and optimisation across the therapeutic antibody pipeline. "We believe AI-driven molecule design, discovery and optimisation will be a key accelerator of our productivity moving forward," said Anastasia Hager, Global Head of Drug Discovery Sciences at Bayer's Pharmaceuticals Division. "Cradle's platform provides us with scalable scientist-centric solutions to maximise the opportunities in our biologics portfolio and potentially deliver faster, more effective medicines to patients." "Bayer's decision reflects a broader shift we're seeing: leading drug discovery organisations want AI that scales across portfolios, formats, and teams without requiring every scientist to become an ML expert or limiting AI's impact to asset-based deals," added Stef van Grieken, Co-Founder and CEO of Cradle. "Cradle brings enterprise-grade, lab-in-the-loop AI into the hands of the expert scientists working daily to design new molecules and treat diseases, helping reduce iterations while improving potency, developability, and manufacturability. We're excited to work with Bayer to operationalise AI at scale and translate it into faster, higher-quality candidates for the clinic." Under the agreement, Cradle will provide Bayer's antibody scientists with full access to its scientific AI software platform supporting a lab-in-the-loop approach, streamlined design-test-learn cycles, and coordinated execution across laboratory and external partners. Bayer and Cradle will also jointly work on a machine learning research project aimed at extending these capabilities even further.